
The foundation is overwhelmingly dedicated to providing direct prescription drug assistance to individual patients in need, funding a patient assistance program that covers medication costs for low-income, ill, and infant populations. Nearly all recorded giving is funneled into a single patient-focused program rather than to nonprofit intermediaries or diverse causes, indicating a mission centered on access to medicines for vulnerable individuals.
Extremely concentrated: virtually all funding is directed to a single patient assistance program across a very small number of grants. The foundation makes very large, program-specific disbursements focused on direct-to-patient support rather than diversified or repeat grants to multiple nonprofit organizations.
Bristol-myers Squibb Patient Assistance Foundation Inc directs almost all of its giving to a single purpose: prescription drug assistance for individual patients. The recent record shows three large grants to Individual Patient Programs in Princeton, New Jersey, all labeled for prescription drugs for the care of qualified ill, needy, and infants. That pattern points to a funder built around direct medication support rather than a broad charitable portfolio. The foundation’s active program, the Patient Medicine Assistance Program, provides certain Bristol-Myers Squibb prescription medicines free of charge to eligible patients who need temporary help obtaining listed medicines. The focus is on access to medicines for people facing financial barriers, including low-income patients and individuals with qualifying illnesses. Because the foundation funds individuals, its grantmaking is structured around patient assistance rather than grants to nonprofit intermediaries. Across the latest filings, the foundation’s work is tightly centered on medication access in the United States, with every recorded grant going to a patient-focused program in Princeton.
The foundation’s core work is prescription drug assistance. Its active Patient Medicine Assistance Program provides certain Bristol-Myers Squibb prescription medicines free of charge to eligible patients who need temporary help obtaining listed medicines. That makes medication access, rather than general health programming, the clearest throughline in its grantmaking. Its recent grants also show support for qualified ill, needy, and infant populations through Individual Patient Programs in Princeton, New Jersey. The purpose language consistently ties funding to prescription drugs for care, which places the foundation in direct-service healthcare support. The beneficiary profile is narrow and specific: infants, low-income or needy individuals, and people with qualifying illnesses. The philosophy tags reinforce that pattern with direct service, in-kind support, targeted assistance, and healthcare access support.
The grant-size distribution is extremely large and tightly clustered: p25 is $3,245,667,810, the median is $3,627,470,508, and p75 is $4,009,273,205. That range suggests very high-volume, program-level support rather than many small discretionary awards. The recent record shows repeat funding to the same recipient program across 2023, 2024, and 2025, indicating ongoing support rather than one-off grants. The foundation is a regular funder and funds individuals directly. It also accepts unsolicited requests for its Patient Medicine Assistance Program.
$9.9B
$230.7M
$2.7B
$2.7B
Most grants fall between $3.2B and $4B, with a median of $3.6B.
25th Percentile
$3.2B
Median
$3.6B
75th Percentile
$4B
About 100% of grants go to recipients in NJ.
Sign up for a free Kindora account to access AI-generated insights into this funder's giving patterns, decision-makers, and fit signals.
Get Started FreeFree Kindora accounts unlock side-by-side comparisons with foundations that share this funder's focus areas and giving profile.
Get Started FreeSign up free to see how well your nonprofit fits this funder, get an AI-generated pitch, and unlock similar foundations.
Notable grantees: INDIVIDUAL PATIENT PROGRAMS
Grantmaking is local and entirely concentrated in the United States. All recorded grants in the recent sample went to Princeton, New Jersey, and New Jersey accounts for 100% of grants in the file. The recipient country distribution shows US: 3 grants. The pattern is therefore geographically narrow, with no recorded non-U.S. recipients.
It funds direct prescription drug assistance for individual patients. The active Patient Medicine Assistance Program provides certain Bristol-Myers Squibb prescription medicines free of charge to eligible patients who need temporary help obtaining listed medicines.
The foundation’s grants are aimed at individual patients, including qualified ill, needy, and infant populations. The beneficiary profile also includes low-income or needy individuals and people with qualifying illnesses.
The grant-size distribution is very large: p25 is $3,245,667,810, the median is $3,627,470,508, and p75 is $4,009,273,205. The recent filings show repeated multibillion-dollar program support.
Yes. The active Patient Medicine Assistance Program is listed as accepting unsolicited requests, and it is focused on helping eligible patients obtain listed medicines temporarily.
Its giving is local and concentrated in the United States. In the recent grant sample, all recorded grants went to Princeton, New Jersey, and New Jersey accounts for 100% of grants in the file.
2025
Source: IRS Form 990-PF, fiscal year 2025.
Most recent grants reported to the IRS.
| Recipient | Location | Amount | Year | Purpose |
|---|---|---|---|---|
| INDIVIDUAL PATIENT PROGRAMS | PRINCETON, NJ | $2,658,494,866 | 2025 | PRESCRIPTION DRUGS FOR CARE OF QUALIFIED ILL, NEEDY, AND INFANTS |
| INDIVIDUAL PATIENT PROGRAMS | PRINCETON, NJ | $4,391,075,903 | 2024 | PRESCRIPTION DRUGS FOR CARE OF QUALIFIED ILL, NEEDY, AND INFANTS |
| INDIVIDUAL PATIENT PROGRAMS | PRINCETON, NJ | $2,863,865,112 | 2023 | PRESCRIPTION DRUGS FOR CARE OF QUALIFIED ILL, NEEDY, AND INFANTS |
INDIVIDUAL PATIENT PROGRAMS
$2,658,494,866PRESCRIPTION DRUGS FOR CARE OF QUALIFIED ILL, NEEDY, AND INFANTS
INDIVIDUAL PATIENT PROGRAMS
$4,391,075,903PRESCRIPTION DRUGS FOR CARE OF QUALIFIED ILL, NEEDY, AND INFANTS
INDIVIDUAL PATIENT PROGRAMS
$2,863,865,112PRESCRIPTION DRUGS FOR CARE OF QUALIFIED ILL, NEEDY, AND INFANTS